Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.5551
−$0.0407 · -6.83%
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Regular session
$0.5551
−$0.0407 · -6.83%
Regular session · ET · Market data may be delayed.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Day range
Current $0.5551
52-week range
Current $0.5551
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
56
Mixed
Risk
65
High Risk
Momentum
38
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
Day range
Current $0.5551
52-week range
Current $0.5551
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 13.31M USD | 15.44M USD | 13.35M USD | 11.37M USD | 12.92M USD |
| Selling, general, and administrative | 15.41M USD | 10.1M USD | 11.82M USD | 8.18M USD | 12.86M USD |
| Operating expenses | 28.73M USD | 25.54M USD | 25.47M USD | 19.84M USD | 26.23M USD |
| Interest income | 529.64K USD | 1.2M USD | 1.33M USD | 528K USD | — |
| Depreciation and amortization | 70K USD | 87K USD | 303.78K USD | 288.83K USD | 452K USD |
| Operating income | −28.73M USD | −25.54M USD | −25.47M USD | −19.84M USD | −26.23M USD |
| Net income | −28.76M USD | −22.79M USD | −20.92M USD | −18.3M USD | −26.3M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
